Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale ... (ur dependence onthird parties for clinic...)

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

Date:9/5/2007

ur dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

[1] FLOMAX is a registered trademark of Boehringer Ingelheim

[2] CARDURA is a registered trademark of Pfizer, Inc.

[3] HYTRIN is a registered trademark of Abbott Laboratories

[4] PROSCAR is a registered trademark of MERCK & CO., Inc.

[5] AVODART is a registered trademark of GlaxoSmithKline

COMPANY CONTACTS MEDIA CONTACT

Russell Skibsted Susan Neath

SVP & Chief Business Officer Porter Novelli Life Sciences

619-849-6007

Paul Arndt

Manager, Investor Relations

949-788-6700

1

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale ...(ur dependence onthird parties for clinic...),Health